Abivax presents preclinical data for obefazimod

Abivax (ABVX) announced novel preclinical and clinical data for obefazimod as part of the presentations at The European Crohn’s and Colitis Organization’s, ECCO, 21st Annual Congress. These data further expand the evidence base supporting development of obefazimod for inflammatory bowel disease, highlighting its anti-fibrotic potential in Crohn’s disease, a favorable safety and tolerability profile, rapid onset of symptomatic relief, and additional evidence supporting its mechanism of action in restoring immune balance through upregulation of miR-124. Highlights: 22 abstracts presented at European Crohn’s and Colitis Organization’s 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod’s potential in inflammatory bowel disease; Anti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, suggesting potential to address a major unmet need in Crohn’s disease; A pooled analysis of safety data from ABTECT-1 and ABTECT-2 induction trials demonstrates a favorable safety profile with rates of serious treatment emergent adverse events and study discontinuation similar to placebo; Symptomatic response of obefazimod was observed as early as week 1 with symptomatic remission observed at week 2 in a pooled analysis of ABTECT-1 and ABTECT-2; Biomarker data from ABTECT-1 and ABTECT-2 induction trials indicate upregulation of miR-124 and reduction of key inflammatory cytokines toward homeostatic levels.